Semaglutid is a medication used in the treatment of obesity and weight management. It is a glucagon-like peptide-1 (GLP-1) receptor agonist that works by mimicking the effects of the hormone GLP-1, which is involved in regulating appetite and food intake. By enhancing feelings of fullness and reducing hunger, Semaglutid can assist individuals in achieving weight loss goals when combined with a reduced-calorie diet and increased physical activity.
The medication is typically prescribed for adults with a body mass index (BMI) of 30 or greater, or for those with a BMI of 27 or greater who have weight-related health conditions. Clinical studies have demonstrated that Semaglutid can lead to significant weight loss compared to placebo treatments. It is administered via subcutaneous injection, and the dosage may be adjusted based on individual response and tolerance.
In addition to its primary use for weight loss, Semaglutid has also been studied for its potential benefits in managing type 2 diabetes. As a result, it may be prescribed to patients who have both obesity and diabetes, addressing multiple health concerns simultaneously. It is important for individuals considering this treatment to consult healthcare professionals for personalized advice and to discuss potential risks and benefits.